Ketoconazole (R 41400)

Catalog No.S1353

For research use only.

Ketoconazole (R 41400) inhibits cyclosporine oxidase and testosterone 6 beta-hydroxylase with IC50 of 0.19 mM and 0.22 mM, respectively. Ketoconazole is an androgen biosynthesis inhibitor.

Ketoconazole (R 41400) Chemical Structure

CAS No. 65277-42-1

Selleck's Ketoconazole (R 41400) has been cited by 12 Publications

Purity & Quality Control

Choose Selective P450 (e.g. CYP17) Inhibitors

Other P450 (e.g. CYP17) Products

Biological Activity

Description Ketoconazole (R 41400) inhibits cyclosporine oxidase and testosterone 6 beta-hydroxylase with IC50 of 0.19 mM and 0.22 mM, respectively. Ketoconazole is an androgen biosynthesis inhibitor.
Features More active than both Econazole and Miconazole against Malassezia species.
Targets
Cyclosporine oxidase [1] Testosterone 6 beta-hydroxylase [1]
0.19 mM 0.22 mM
In vitro

Ketoconazole interacts with androgen receptors in a competitive fashion in intact human foreskin fibroblasts. Ketoconazole competes for [3H]dexamethasone binding to fibroblast glucocorticoid receptors with IC50 of 0.3 mM. [2] Ketoconazole reduces cell proliferation and [3H]thymidine incorporation with IC50 of 2.5 mM in the serum independent HT29-S-B6 colon cell clone. Ketoconazole inhibits the incorporation of [3H]thymidine with IC50 of 2 μM and 13 μM in the Evsa-T cell line and MDA-MB-231 cell line, respectively. Ketoconazole induces a decrease of the number of cells in S phase and a corresponding increase of the percentage of cells in Go-G1 in HT29-S-B6 cells. [3] Ketoconazole is susceptable to several Malassezia species with minimum inhibitory concentrations (MICs) of 0.03 µg/mL. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LLC-PK1 epithelial cells MXzGeY5kfGmxbjDhd5NigQ>? NGTn[nhKdmirYnn0bY9vKG:oIGCt[4x6[2:ycn;0[YlvNCCqdX3hckBNNU2GUkGg[ZhxemW|c3XkJIlvKEyOQz3QT|Eh\XCrdHjlcIlidCClZXzsd{B2e2mwZzDjZYxk\WmwLVHNJJBwdGG{aYPheIlwdiCjc4PhfUwhUUN3ME20Mlgh|ryP MWGxNlY6QTN6OR?=
MCF7 cells NH3zcXFHfW6ldHnvckBie3OjeR?= MoPlTY5pcWKrdHnvckBw\iCFWWCyOmEyKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgZYxtNXS{YX7zJJJmfGmwb3njJIFkcWRibXX0ZYJwdGm|bTygTWM2OD1zMjFOwG0> M1;3c|E3Ojd7N{ew
human THP1 cells NIX5WYhEgXSxdH;4bYNqfHliYYPzZZk> NHTweIE1QCCq NEjCRWFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVUFBzIHPlcIx{KGGodHXyJFQ5KGi{czygTWM2OD12NDFOwG0> MknHNVc6PjB7MkO=
CHO cells M{H0SmZ2dmO2aX;uJIF{e2G7 NYe0NZVSUW6qaXLpeIlwdiCxZjDDXXAzPEFzIHX4dJJme3OnZDDpckBEUE9iY3XscJMtKEmFNUC9NE42OiEQvF2= NIHlcWozODZ3NU[yOi=>
P815B cells MnjYR5l1d3SxeHnjbZR6KGG|c3H5 M4[1U|I1KGh? NEC3SG9EgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBRQDF3QjDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSVL2DNV{Bie3OjeTygUGQ2OD1{NTFOwG0> NWjnUVRzOjVyM{[3PFk>
V79 11B2 cells NULMOXpNTnWwY4Tpc44h[XO|YYm= NYDoOIZQUW6qaXLpeIlwdiCxZjDoeY1idiCFWWCxNWIzKGW6cILld5Nm\CCrbjDWO|khOTGEMjDj[YxteyxiSVO1NF0xNjB6MTFOwG0> NIH6V4syPjV5MEmxPC=>
V79 cells NUC3OYtGTnWwY4Tpc44h[XO|YYm= MmLpTY5pcWKrdHnvckBw\iCqdX3hckBEYVB{NDDofYRzd3i7bHHz[UBmgHC{ZYPz[YQhcW5iVke5JINmdGy|LDDJR|UxRTBwM{GyJO69VQ>? MWexOVYyPTV|NB?=
hamster V79MZh11B1 cells M2jyUWZ2dmO2aX;uJIF{e2G7 NELsdVBKdmirYnn0bY9vKG:oIHj1cYFvKEO\UEGxRlEh\XiycnXzd4VlKGmwIHjhcZN1\XJiVke5UXppOTGEMTDj[YxteyxiSVO1NF0xNjF{NzFOwG0> MXixPFY4Ojh4OB?=
hamster V79MZh11B2 cells NHGxOZNHfW6ldHnvckBie3OjeR?= NGSzdHBKdmirYnn0bY9vKG:oIHj1cYFvKEO\UEGxRlIh\XiycnXzd4VlKGmwIHjhcZN1\XJiVke5UXppOTGEMjDj[YxteyxiSVO1NF0xNjB4NzFOwG0> NHnOVXUyQDZ5Mki2PC=>
CHO cells M3LNbmZ2dmO2aX;uJIF{e2G7 MortTY5pcWKrdHnvckBw\iCqdX3hckBGWkdiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{BjgSC5aH;s[UBk\WyuIIDheINpKGOuYX3wJJRm[2iwaYH1[UwhUUN3ME2xMlkxPTR4IN88US=> Mm[yNVg1PDh|NEK=
V79 11B1 cells MULGeY5kfGmxbjDhd5NigQ>? NXTpNWhNUW6qaXLpeIlwdiCxZjDoeY1idiCFWWCxNWIyKGW6cILld5Nm\CCrbjDWO|khOTGEMTDj[YxteyxiSVO1NF0xNjJ{NDFOwG0> NVL4dlZxOTZ3N{C5NVg>
Topp 3 cells MV\GeY5kfGmxbjDhd5NigQ>? NEe1Z|RKdmirYnn0bY9vKG:oIHj1cYFvKEO\UEWxJIV5eHKnc4Pl[EBqdiCWb4DwJFMh[2WubIOgZpkhdGGwb4P0[ZJwdCCmZX3leIh6dGG|ZTDhd5NigSxiSVO1NF0xNjF7IN88US=> NV3QTIxzOTdzOUS3NVY>
V79 cells NH;PUVdHfW6ldHnvckBie3OjeR?= NF\EZZpKdmirYnn0bY9vKG:oIHj1cYFvKEO\UEK0RVEh\XiycnXzd4VlKGmwIHPobY5me2ViaHHtd5RmeiCYN{mgZ4VtdHNuIFnDOVA:OC5|MUKg{txO NHjHZ|QzODV7NEi2Ni=>
V79MZ cells M1\W[mZ2dmO2aX;uJIF{e2G7 M2TKWmlvcGmkaYTpc44hd2ZiaIXtZY4hS1mSMUHCNkBmgHC{ZYPz[YQhcW5iaHHtd5RmeiCYN{nNXkBk\WyuczD1d4lv\yBzMT3k[Y95gWOxcoTpZ49{fGW{b37lJJN2[nO2cnH0[UwhUUN3ME2wMlA3PyEQvF2= NXfnNHFHOjR7MECyOFc>
V79MZh cells NGnvcYFHfW6ldHnvckBie3OjeR?= M2jGcmlvcGmkaYTpc44hd2ZiaIXtZY4hS1mSMUHCNkBmgHC{ZYPz[YQhcW5iaHHtd5RmeiCYN{nNXogh[2WubIOsJGlEPTB;MD6wOlch|ryP MnXDNlA2PTBzMUi=
human epidermal keratinocytes NYnITWhHTnWwY4Tpc44h[XO|YYm= NV3UVGI5UW6qaXLpeIlwdiCxZjDDXXAzPEFzIHnuJIh2dWGwIHXwbYRmem2jbDDr[ZJifGmwb3P5eIV{NCCLQ{WwQVAvOTJ4IN88US=> MWWyNFU6PDh4Mh?=
V79MZh cells NWD2UFhlTnWwY4Tpc44h[XO|YYm= MVXJcohq[mm2aX;uJI9nKGi3bXHuJGN[WDFzQkGg[ZhxemW|c3XkJIlvKGijbYP0[ZIhXjd7TWroJINmdGy|LDDJR|UxRTBwMUK3JO69VQ>? NH7IOJYzODV3MEGxPC=>
In vivo Ketoconazole (25 mg/kg, i.p.) significantly decreases plasma corticosterone and reduces low dose cocaine self-administration without affecting food-reinforced responding in rats. [5] Ketoconazole raises the AUC of orally administered digoxin from 63 mg x h/L to 411 mg x h/L in rats. Ketoconazole raises the AUC of intravenously administered digoxin from 93 mg × h/L to 486 mg × h/L in rats. Ketoconazole increases digoxin bioavailability from 0.68 to 0.84 in rats, while mean absorption time is reduced from 1.1 hours to 0.3 hour. [6]

Protocol (from reference)

Kinase Assay:[1]
  • Whole Cell [3H]R1881 Binding Assay:

    Fibroblasts are grown to confluence in five or six 150 cm2 tissue culture flasks for routine assay. This usually requires 4-6 weeks from the time of the initial seeding of the cell line. All studies are performed between passages 3-20. Two days before assay, the medium is changed to one lacking fetal calf serum. This is repeated again 24 hours before assay. Competition assays are performed with 0.5-1.0 nM [3H]R1881 and increasing amounts of the nonradioactive compounds. Binding to low affinity sites is determined in the presence of 5 × 10-7 M R1881 and is subtracted from whole cell binding of [3H]R 1881 obtained in the absence of any inhibitor to assess binding to 5 high affinity site

Cell Research:[3]
  • Cell lines: HT29-S-B6 colon cell
  • Concentrations: 25 μM
  • Incubation Time: 72 hours
  • Method: HT29-S-B6 cells (5×105) are plated in 35-mm Petri dishes. The next day, the medium is changed and effectors are added in a small volume (10-20 μL). The incubation medium is renewed every day during the experiments. The same triplicate dishes are used for cell counts, [3H]thymidine incorporation, and flow cytometry. [3H]Thymidine (0.5 μCi) is allowed to incorporate for 24 hours; at the end of incubation, cells are rinsed with 1 mL of medium, detached with 1 mL of trypsin-EDTA, and diluted (1:3) with the culture medium. An aliquot (0.5-1 mL) is used for cell count with a Coulter Counter.
Animal Research:[4]
  • Animal Models: male Wistar rats
  • Dosages: 25 mg/kg
  • Administration: Intraperitoneal injection

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 531.43
Formula

C26H28Cl2N4O4

CAS No. 65277-42-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04869449 Recruiting Drug: Ketoconazole Glioblastoma|Glioblastoma Multiforme|Glioblastoma Multiforme of Brain|Glioblastoma Multiforme Adult Milton S. Hershey Medical Center May 12 2022 Early Phase 1
NCT04212000 Completed Drug: Levoketoconazole|Drug: Ketoconazole Healthy Cortendo AB December 16 2019 Phase 1
NCT03796273 Recruiting Other: Best Practice|Drug: Ketoconazole Anatomic Stage IV Breast Cancer AJCC v8|Astrocytoma|Breast Carcinoma Metastatic in the Brain|Glioma|Invasive Breast Carcinoma|Oligodendroglioma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Glioma Wake Forest University Health Sciences|National Cancer Institute (NCI) March 13 2019 Early Phase 1
NCT04872920 Recruiting -- Cushing Syndrome HRA Pharma December 20 2018 --
NCT03473418 Unknown status Drug: Ketoconazole|Drug: Terconazole Vaginal Candidiasis Assiut University April 1 2018 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Ketoconazole (R 41400) | Ketoconazole (R 41400) supplier | purchase Ketoconazole (R 41400) | Ketoconazole (R 41400) cost | Ketoconazole (R 41400) manufacturer | order Ketoconazole (R 41400) | Ketoconazole (R 41400) distributor